Education
About Us
Working with TipRanks
Follow Us
Tengion Inc (TNGNQ)
OTHER OTC:TNGNQ
TNGNQ Stock Chart & Stats
$0.01
<$0.01(900.00%)
At close: 4:00 PM EST
$0.01
<$0.01(900.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume2.64K
Average Volume (3M)N/A
Market Cap
$40.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta32.04
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,245,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TNGNQ FAQ
What was Tengion Inc’s price range in the past 12 months?
Currently, no data Available
What is Tengion Inc’s market cap?
Tengion Inc’s market cap is $40.00.
When is Tengion Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tengion Inc’s earnings last quarter?
Currently, no data Available
Is Tengion Inc overvalued?
According to Wall Street analysts Tengion Inc’s price is currently Overvalued.
Does Tengion Inc pay dividends?
Tengion Inc does not currently pay dividends.
What is Tengion Inc’s EPS estimate?
Tengion Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tengion Inc have?
Tengion Inc has 40,245,000 shares outstanding.
What happened to Tengion Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tengion Inc?
Currently, no hedge funds are holding shares in TNGNQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tengion Inc
Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials that are implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Its product portfolio includes Neo-Kidney Augment to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease; and Neo-Urinary Conduit, which is in Phase I clinical trial and used to replace the use of bowel tissue in bladder cancer patients requiring a non-continent urinary diversion after bladder removal surgery. The company has a license agreement with Children's Medical Center Corporation (CMCC) for the license of certain patent rights and intellectual property rights owned or controlled by CMCC related to tissue engineering technology. Tengion, Inc. was founded in 2003 and is headquartered in Winston-Salem, North Carolina. On December 29, 2014, Tengion, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Technical Analysis
Nuwellis
―
―
Scinai Immunotherapeutics
―
PainReform
―
Virax Biolabs Group Ltd. Class A
―